The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Current and future ophthalmic drug delivery systems
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Self-citationDUFES, C., UCHEGBU, I., & SCHATZLEIN, A. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.017 · Cited by 984
DNA-based therapeutics and DNA delivery systems: A comprehensive review
Patil, S. D., Rhodes, D. G., & Burgess, D. J. (2005) · The AAPS Journal · doi:10.1208/aapsj070109 · Cited by 630
Sieving, P. A., Caruso, R. C., Tao, W., Coleman, H. R., Thompson, D. J. S., Fullmer, K. R., & Bush, R. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600236103 · Cited by 589
Fluocinolone Acetonide Implant (Retisert) for Noninfectious Posterior Uveitis
Jaffe, G. J., Martin, D., Callanan, D., Pearson, P. A., Levy, B., & Comstock, T. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.021 · Cited by 454
Kuppermann, B. D. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.3.309 · Cited by 429
Bourges, J.-L., Gautier, S. E., Delie, F., Bejjani, R. A., Jeanny, J.-C., Gurny, R., BenEzra, D., & Behar-Cohen, F. F. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1068 · Cited by 357
Permeability of Retinal Pigment Epithelium: Effects of Permeant Molecular Weight and Lipophilicity
Pitka¨nen, L., Ranta, V.-P., Moilanen, H., & Urtti, A. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-1051 · Cited by 261
Self-citationGold nanoparticles enable selective light-induced contents release from liposomes
Paasonen, L., Laaksonen, T., Johans, C., Yliperttula, M., Kontturi, K., & Urtti, A. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.06.009 · Cited by 252
Self-citation
Cited by
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Ocular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Self-citationApplications of nanoparticles in ophthalmology
Diebold, Y., & Calonge, M. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.08.002 · Cited by 392
Chitosan-based nanostructures: A delivery platform for ocular therapeutics
de la Fuente, M., Raviña, M., Paolicelli, P., Sanchez, A., Seijo, B., & Alonso, M. J. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.026 · Cited by 354
Drug delivery to the posterior segment of the eye
Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C., & Alany, R. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.004 · Cited by 335
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330
“The leading causes of blindness in the industrialized world are diseases that affect the back of the eye (1).”
Recent Advances in Ophthalmic Drug Delivery
Kompella, U. B., Kadam, R. S., & Lee, V. H. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.40 · Cited by 285
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
A review on therapeutic contact lenses for ocular drug delivery
Maulvi, F. A., Soni, T. G., & Shah, D. O. (2016) · Drug Delivery · doi:10.3109/10717544.2016.1138342 · Cited by 270
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“Iontophoresis is the application of electrical current to drive ionized substances into tissue (del Amo and Urtti, 2008).”
Niosomal drug delivery systems for ocular disease-recent advances and future prospects
Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., & Zarrabi, A. (2020) · Nanomaterials · doi:10.3390/nano10061191 · Cited by 196
Advances in ophthalmic drug delivery
Morrison, P. W., & Khutoryanskiy, V. V. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.75 · Cited by 196
Nanotherapy for posterior eye diseases
Kaur, I. P., & Kakkar, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.031 · Cited by 175
Xu, J., Ge, Y., Bu, R., Zhang, A., Feng, S., Wang, J., Gou, J., Yin, T., He, H., Zhang, Y., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.025 · Cited by 126
Polyhydroxyethylaspartamide-based micelles for ocular drug delivery
Civiale, C., Licciardi, M., Cavallaro, G., Giammona, G., & Mazzone, M. G. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.028 · Cited by 120
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Di Tommaso, C., Torriglia, A., Furrer, P., Behar-Cohen, F., Gurny, R., & Möller, M. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.004 · Cited by 84
Drug delivery via the suprachoroidal space for the treatment of retinal diseases
Naftali Ben Haim, L., & Moisseiev, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070967 · Cited by 68
Use of rabbit eyes in pharmacokinetic studies of intraocular drugs
Ahn, S. J., Hong, H. K., Na, Y. M., Park, S. J., Ahn, J., Oh, J., Chung, J. Y., Park, K. H., & Woo, S. J. (2016) · Journal of Visualized Experiments · doi:10.3791/53878 · Cited by 60
pH-Responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy
Guo, S., Li, C., Wang, C., Cao, X., Liu, X., Liang, X.-J., Huang, Y., & Weng, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.001 · Cited by 36
Design of Nanotechnological Carriers for Ocular Delivery of Mangiferin: Preformulation Study
Santonocito, D., Vivero-Lopez, M., Lauro, M. R., Torrisi, C., Castelli, F., Sarpietro, M. G., & Puglia, C. (2022) · Molecules · doi:10.3390/molecules27041328 · Cited by 32
“The use of conventional eye drops is limited by precorneal drug removal mechanisms and physiological barriers [2,3] that oppose drug penetration, limiting the ocular bioavailability to 5–10% [4].”
BackgroundViral-vector-delivered anti-angiogenic therapies to the eye
Koponen, S., Kokki, E., Kinnunen, K., & Ylä-Herttuala, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020219 · Cited by 24
“The ocular tissues can be reached by either local or systemic administration [3].”
BackgroundDevi, S., Saini, V., Kumar, M., Bhatt, S., Gupta, S., & Deep, A. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190726162000 · Cited by 21
Metadata
- Authors
- del Amo, E. M., & Urtti, A.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 13
- Issue
- 3-4
- Pages
- 135-143
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2055499548
- Cited by
- 414
- References
- 50
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.